Journal of Clinical Oncology, Vol 19, Issue 10
(May), 2001: 2607-2615
© 2001 American Society for Clinical Oncology
Detection of Epstein-Barr Virus DNA in the Peripheral-Blood Cells of Patients With Nasopharyngeal Carcinoma: Relationship to Distant Metastasis and Survival
By Jin-Ching Lin,
Kuang Y. Chen,
Wen-Yi Wang,
Jian-Sheng Jan,
Wen-Miin Liang,
Chia-Shing Tsai,
Yau-Huei Wei
From the Institute of Clinical Medicine, College of Medicine, and Department of Biochemistry and Center for Cellular and Molecular Biology, School of Life Science, National Yang-Ming University; Department of Radiation Oncology, Taichung Veterans General Hospital; Taipei Veterans General Hospital, Taipei; Cancer Center, Department of Basic Medicine, Hung Kuang Institute of Technology; and School of Public Health, China Medical College, Taichung, Taiwan.
Address reprint requests to Yau-Huei Wei, PhD, Department of Biochemistry and Center for Cellular and Molecular Biology, School of Life Science, National Yang-Ming University, No 155, Li-Nong St, Sec 2, Taipei, 112 Taiwan; email: joeman{at}ym.edu.tw
PURPOSE: Nasopharyngeal carcinoma (NPC) has been proved to be an Epstein-Barr virus (EBV)-associated cancer. By use of nested polymerase chain reactions (PCRs), we examined whether the presence of EBV DNA in the peripheral-blood cells (PBC) can serve as a prognostic indicator for NPC.
PATIENTS AND METHODS: Peripheral blood from 124 patients with NPC who had no evidence of distant metastasis and 114 healthy volunteers with serologically positive findings for EBV infection was collected prospectively. Plasma and erythrocytes were separated. DNA was extracted from PBCs and analyzed by a nested PCR using primers specific to Epstein-Barr virus nuclear antigen 1 (EBNA-1). All patients were treated by radiotherapy with or without chemotherapy. Clinical parameters and status of EBNA-1 in PBCs were used for survival analysis using the Kaplan-Meier method and the Cox proportional hazards model.
RESULTS: Positive rates of EBNA-1 DNA in PBCs of NPC patients and healthy volunteers are 71% and 14%, respectively (P = .001). No significant difference was observed with regard to the clinical characteristics of patients who were EBNA-1–positive (n = 88) and those who were EBNA-1–negative (n = 36). After a median follow-up period of 38 months (range, 24 to 56 months), 29 of 88 EBNA-1–positive patients and only one of 36 EBNA-1–negative patients developed distant metastases (P = .00015). Kaplan-Meier estimates of overall survival (P = .0010), metastasis-free survival (P = .0004), and progression-free survival (P = .0004) were significantly lower for the patients in the EBNA-1–positive group than for those in the EBNA-1–negative group. Multivariate Cox analysis confirmed the same results.
CONCLUSION: The presence of EBNA-1 DNA in PBCs is a novel, important risk factor for patients with NPC that indicates a significantly higher risk of developing distant metastasis as well as a lower survival rate.
This article has been cited by other articles:
|
|
|
|
 
W. J. Maloney and M. A. Weinberg
A Comprehensive Analysis of Babe Ruth's Head and Neck Cancer
J Am Dent Assoc,
July 1, 2008;
139(7):
926 - 932.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-C. Chen, I.-J. Feng, C.-H. Lu, C.-C. Chen, J.-T. Lin, S.-H. Huang, and K.-D. Lee
The incidence and risk of second primary cancers in patients with nasopharyngeal carcinoma: a population-based study in Taiwan over a 25-year period (1979-2003)
Ann. Onc.,
June 1, 2008;
19(6):
1180 - 1186.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. T. Chang and H.-O. Adami
The enigmatic epidemiology of nasopharyngeal carcinoma.
Cancer Epidemiol. Biomarkers Prev.,
October 1, 2006;
15(10):
1765 - 1777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q.-T. Le, C. D. Jones, T.-K. Yau, H. A. Shirazi, P. H. Wong, E. N. Thomas, B. K. Patterson, A. W.M. Lee, and J. L. Zehnder
A Comparison Study of Different PCR Assays in Measuring Circulating Plasma Epstein-Barr Virus DNA Levels in Patients with Nasopharyngeal Carcinoma
Clin. Cancer Res.,
August 15, 2005;
11(16):
5700 - 5707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. C. Stevens, S. A. W. M. Verkuijlen, B. Hariwiyanto, Harijadi, J. Fachiroh, D. K. Paramita, I. B. Tan, S. M. Haryana, and J. M. Middeldorp
Diagnostic Value of Measuring Epstein-Barr Virus (EBV) DNA Load and Carcinoma-Specific Viral mRNA in Relation to Anti-EBV Immunoglobulin A (IgA) and IgG Antibody Levels in Blood of Nasopharyngeal Carcinoma Patients from Indonesia
J. Clin. Microbiol.,
July 1, 2005;
43(7):
3066 - 3073.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. C.W. Lit, K.C. A. Chan, S.-F. Leung, K. I.K. Lei, L. Y.S. Chan, K. C.K. Chow, A. T.C. Chan, and Y.M. D. Lo
Distribution of Cell-Free and Cell-Associated Epstein-Barr Virus (EBV) DNA in the Blood of Patients with Nasopharyngeal Carcinoma and EBV-Associated Lymphoma
Clin. Chem.,
October 1, 2004;
50(10):
1842 - 1845.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-C. Lin, W.-Y. Wang, K. Y. Chen, Y.-H. Wei, W.-M. Liang, J.-S. Jan, and R.-S. Jiang
Quantification of Plasma Epstein-Barr Virus DNA in Patients with Advanced Nasopharyngeal Carcinoma
N. Engl. J. Med.,
June 10, 2004;
350(24):
2461 - 2470.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. H. Yu, Y. M. D. Lo, G. M. Tse, K. C. A. Chan, A. B. W. Chan, K. C. K. Chow, T. K. F. Ma, A. C. Vlantis, S. F. Leung, C. A. van Hasselt, et al.
Quantitative Analysis of Cell-Free Epstein-Barr Virus DNA in Plasma of Patients with Nonnasopharyngeal Head and Neck Carcinomas
Clin. Cancer Res.,
March 1, 2004;
10(5):
1726 - 1732.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-Y. Wang, Y.-C. Chien, J.-S. Jan, C.-M. Chueh, and J.-C. Lin
Consistent Sequence Variation of Epstein-Barr Virus Nuclear Antigen 1 in Primary Tumor and Peripheral Blood Cells of Patients with Nasopharyngeal Carcinoma
Clin. Cancer Res.,
August 1, 2002;
8(8):
2586 - 2590.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
